GSK PLC GSK shares slipped 2.45% to £15.36 Friday, on what proved to be an all-around grim trading session for the stock ...

Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high ...

This Fool wants to make the most of the benefits a Stocks and Shares ISA provides. He's keen on these two stocks. The post I ...

First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.

FluMist is the first vaccine to prevent influenza that does not need to be administered by a healthcare provider, the ...

The mum was enjoying a holiday long-weekend with her husband and children when she got the gut feeling something wasn't right.

The inoculation campaign is expected to lower the mortality rate in children, as malaria makes up 19 percent of child deaths ...

FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.

Our Fool likes the look of these stock market juggernauts for the chunky passive income they throw off, not to mention their ...

Niger has become the latest West African country to roll out malaria vaccines to try to stifle the potentially deadly disease, an official source told AFP on Friday.